A Phase 2 interventional study of KH658 Dose 1 and KH658 Dose 2 in Diabetic Retinopathy, sponsored by Chengdu Origen Biotechnology Co., Ltd.. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Chengdu Origen Biotechnology Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Diabetic Retinopathy with a site in China — 27 open to participants now, 28 under way, 2 of them phase 3. Diabetic Retinopathy · China.
Among the 85 studies in Diabetic Retinopathy with a site in China, this one is the 49th largest by planned enrollment of the 56 interventional ones that give a count, is the only one that started in 2027, is one of 6 in phase 2, reaches primary completion later than 23 of the 27 other live ones, and was the 85th registered.
783 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.
Browse Diabetic Retinopathy studies →27 of the 85 studies in Diabetic Retinopathy with a site in China are open now. Recruiting first, the newest first:
Qilu Hospital of Shandong University · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Beletalent (Zhuhai) Pharmaceutical Co., Ltd · Sites in China
Ages 18–75
Xuxiang Zhang, MD · Sites in China
Ages 40–80
Yufan Wang · Sites in China
Ages 20–79
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 7 · Phase 4 5
First in 2008; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 80 across 482 interventional studies indexed under Diabetic Retinopathy.
Median enrollment 139 across the 56 interventional studies, 769 across the 29 observational. Of the 30 that completed or were terminated, 2 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 85 have an industry lead sponsor. The 10 most frequent:
Chengdu Origen Biotechnology Co., Ltd. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Chengdu Origen Biotechnology Co., Ltd. has 1 study filed under Diabetic Retinopathy — fewer than ten, so there is no comparison to draw.
3 of the studies in Diabetic Retinopathy with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06272565Zhongshan Ophthalmic Center, Sun Yat-sen UniversityExploring the Interaction Between Metabolic Disorders and NLPR3 Inflammasome Activation in DR Inflammatory Damage | 2026-12-30 |
| NCT07201415Zhongnan HospitalMinimally Invasive Suprachoroidal Drainage for the Treatment of Neovascular Glaucoma | 2026-12-31 |
| NCT06610747Zhongshan Ophthalmic Center, Sun Yat-sen UniversityHome- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT | 2027-04-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 85 studies in Diabetic Retinopathy with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
KH658 is a adeno-associated virus (AAV) vector-based gene therapy for suprachoroidal space injection. The long-term, stable therapeutic protein after one time injection for DR could potentially reduce the treatment burden and maintain visual acuity and retinal anatomical stability
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In-office delivers KH658 to the suprachoroidal space
Genetic: KH658 Dose 1
In-office delivers KH658 to the suprachoroidal space
Genetic: KH658 Dose 2
Ranibizumab IVT Injection
Drug: Ranibizumab
Observational Control
KH658 Dose 1 suprachoriodal single injection
KH658 Dose 2 suprachoriodal single injection
Administered by intravitreal injection once a month
Proportion of Participants with a ≥2 steps DRSS Improvement From Baseline in Diabetic Retinopthy
To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the proportion of participants achieving a ≥2 steps improvement on the DRSS from baseline.
Time frame: At Week 52
Proportion of Participants Developing Vision-Threatening Events (VTEs)
To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the proportion of participants developing VTEs. VTEs include vision-threatening complications (VTCs) and center-involved diabetic macular edema (CI-DME) requiring rescue treatment.
Time frame: At Week 52
Proportion of Participants With Improvement, Maintanance, or Worsening in DRSS Score From Baseline
To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the proportion of participants demonstrating improvement, maintance, or worsening in the DRSS score compared to baseline.
Time frame: At Week 24, Week 52
Time to first occurrence of VTEs
To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the time to first occurrence of VTEs.
Time frame: Day 1 to Week 52
Incidence of adverse events (AEs) and serious adverse events (SAEs)
To evaluate the safty of KH658 ophthalmic injection in patients with DR, assessed by the incidence of AEs and SAEs
Time frame: Through Week 52
Number of rescue treatments
To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the number of rescue treatments
Time frame: At Week 24, Week 52
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2027; primary completion for Jun 2028, 16 months later.
Of 30 industry-sponsored phase 2 interventional studies under Diabetic Retinopathy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 37. This study's planned 16 months is below that.
Counting every sponsor, half of 43 studies reached it within 31 months; a quarter within 17 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chengdu Origen Biotechnology Co., Ltd.